Targeting DC using anti-mClec9A mAb induces potent humoral responses. (A,B) Mice were injected intravenously with either 2 μg (n = 5), 0.4 μg (n = 5), 0.08 μg (n = 5), or 0.016 μg (n = 4) anti-mClec9A mAb (10B4) or with 50 μg (n = 5) and 10 μg (n = 5) of a nontargeting isotype control mAb-1 (eBioscience), or with 50 μg (n = 2) of an in-house isotype control mAb-2 (GL117). Serum anti-rat reactivity was measured by ELISA on week 2 (A) and week 4 (B). Mean titers plus or minus SEM are depicted. The titration experiment was performed twice. The 10-μg dose response represents the cumulative data of 5 experiments (week 2, n = 20; week 4, n = 19). (C) Mice (n = 5) were injected intravenously with 10 μg of either anti-mClec9A mAb or nontargeting isotype control mAb-1 (eBioscience). Serum samples were collected on weeks 2, 4, and 6, after which mice were injected with 10 μg of nontargeting isotype control mAb-2 (GL117). Serum anti–rat Ig reactivity was measured by ELISA on weeks 2, 4, 6, and 8 and is presented as mean titers plus or minus SEM (D) Mice were injected intravenously with 10 μg of either anti-mClec9A mAb (n = 7) or nontargeting isotype control mAb-2 (GL117; n = 4). The isotype of the serum anti–rat Ig reactivity was measured by ELISA on week 4. Bar graphs depict mean titers plus or minus SEM. The experiments were performed twice.